Intracerebral hemorrhage (ICH) is a commonly spontaneous and potentially fatal condition with a mortality rate as high as 50%, a number not improved upon in the last two decades. Current therapeutic approaches are only moderately effective for a specific group of patients. This technology describes a group of molecular inhibitors that may ameliorate the biological mechanisms responsible for ICH. Further, this technology provides multiple embodiments of complement inhibitors to offer a broad range of potential therapeutic options to prevent or treat injury of ICH.
This technology aims to mitigate the effects of ICH. This inhibition occurs through the administration of one or more molecules identified in this technology as complement inhibitors that suppress the inflammatory response often associated with ICH. Further, the inhibitors identified here allow for broad and increasing effective applicability of this technology via combinations of its numerous inhibitors. This technology, therefore, may provide an effective means to ameliorate and treat ICH.
This technology has been extensively studied in a mouse model and is well-characterized.
Patent Pending (WO/2010/022149)
Tech Ventures Reference: IR 2493